The antitumor activity of the fungicide ciclopirox
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ciclopirox olamine (CPX) is a synthetic antifungal agent clinically used to treat mycoses of the skin and nails. Here, we show that CPX inhibited tumor growth in human breast cancer MDA‐MB‐231 xenografts. To unveil the underlying mechanism, we further studied the antitumor activity of CPX in cell culture. The results indicate that CPX inhibited cell proliferation and induced apoptosis in human rhabdomyosarcoma (Rh30), breast carcinoma (MDA‐MB231) and colon adenocarcinoma (HT‐29) cells in a concentration‐dependent manner. By cell cycle analysis, CPX induced accumulation of cells in G 1/G 0 phase of the cell cycle. Concurrently, CPX downregulated cellular protein expression of cyclins (A, B1, D1 and E) and cyclin‐dependent kinases (CDK2 and CDK4) and upregulated expression of the CDK inhibitor p21 Cip1, leading to hypophosphorylation of retinoblastoma protein. CPX also downregulated protein expression of Bcl‐xL and survivin and enhanced cleavages of Bcl‐2. Z‐VAD‐FMK, a pan‐caspase inhibitor, partially prevented CPX‐induced cell death, suggesting that CPX‐induced apoptosis of cancer cells is mediated at least in part through caspase‐dependent mechanism. The results indicate that CPX is a potential antitumor agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“CPX also inhibits the iron-containing enzymes, such as catalase and peroxidase,(11) which are critical for decomposition of hydrogen peroxide, one of the reactive oxygen species involved in oxidative stress.(28) Whether CPX functions as an anticancer agent through iron chelation remains to be determined.”
BackgroundCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 7×
“During distinct phases of the cell cycle, cyclin/CDK complexes are formed and can guide the CDKs to appropriate substrates and activate their catalytic activity.(15) Early G1 transition is mainly regulated by cyclin D complexed with CDK4 and/or CDK6, whereas late G1-S and early S-phase transitions are regulated by cyc…”
BackgroundMethodInfluentialCellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974 · cited 2×
“The D cyclins and their counterparts CDKs have been suggested to be the most important regulators of Rb phosphorylation.(17,31) In this study, we observed a profound loss of Rb phosphorylation after a 24-hr exposure to CPX in Rh30 cells.”
Background
Cited by
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Brown, R. A. M., Richardson, K. L., Kabir, T. D., Trinder, D., Ganss, R., & Leedman, P. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00476 · Cited by 278
Translation Regulation as a Therapeutic Target in Cancer
Grzmil, M., & Hemmings, B. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0026 · Cited by 103
Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069646 · Cited by 73
“Its effects on galactose metabolism or utilization may help explain why ciclopirox is effective against chronic myeloid leukemia and breast cancer cell lines compared to normal cells [15,73].”
Background
Metadata
- Authors
- Zhou, H., Shen, T., Luo, Y., Liu, L., Chen, W., Xu, B., Han, X., Pang, J., Rivera, C. A., & Huang, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-03-11
- Volume
- 127
- Issue
- 10
- Pages
- 2467-2477
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2017847041
- Cited by
- 106
- References
- 3
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.